Pulmonary Hypertension: A Contraindication for Lung Volume Reduction Surgery?

Historically, pulmonary hypertension (PH) has been considered as one of the contraindications for lung volume reduction surgery (LVRS). Newer studies have shown that LVRS is successful in select emphysema patients with PH.

In-hospital and 1-year functional and quality of life (QOL) outcomes were studied in patients with PH post-LVRS. PH was defined as pulmonary artery pressure (PAP) exceeding 35 mm Hg by right heart catheterization (RHC), where available, or else exceeding 35 mm Hg by echocardiogram.

Of 124 patients who underwent LVRS, 56 (45%) had PH (mean PAP, 41 mm Hg) with 48 mild to moderate and 8 severe PH. In-hospital outcomes were similar between patients with and without PH: hours of artificial ventilation (1.8 vs 0.06, P = .882), days in intensive care (4 vs 6, P = .263), prolonged air leak (12% vs 19%, P = .402), and days of hospital stay (13 vs 16, P = .072). Lung function improved significantly at the 1-year follow-up in patients with PH: forced expiratory volume in 1 second % predicted (26 vs 38, P = .001), forced vital capacity % (62 vs 90, P = .001), residual volume % predicted (224 vs 174, P = .001), diffusion capacity of the lung for carbon monoxide % predicted (36 vs 43, P = .001), 6-minute walk distance test (1104 vs 1232 feet, P = .001), and QOL utility scores (0.67 vs 0.77, P = .001). There were no differences in in-hospital, baseline, and follow-up functional and QOL outcomes between patients with and without PH.

In this small, single-institution cohort, outcomes of patients undergoing LVRS for emphysema with PH were similar to those of patients without PH. LVRS may be a potential option for select emphysema patients with PH.